Detection of PLA2R Autoantibodies before the Diagnosis of Membranous Nephropathy
- 16 December 2019
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American Society of Nephrology
- Vol. 31 (1), 208-217
- https://doi.org/10.1681/asn.2019050538
Abstract
Background Circulating serum autoantibodies against the M-type phospholipase A2 receptor (PLA2R-AB) are a key biomarker in the diagnosis and monitoring of primary membranous nephropathy (MN). However, little is known about the appearance and trajectory of PLA2R-AB before the clinical diagnosis of MN. Methods Using the Department of Defense Serum Repository, we analyzed PLA2R-AB in multiple, 1054 longitudinal serum samples collected before diagnosis of MN from 134 individuals with primary MN, 35 individuals with secondary MN, and 134 healthy volunteers. We evaluated the presence and timing of non-nephrotic range proteinuria (NNRP) and serum albumin measurements in relation to PLA2R-AB status. Results Analysis of PLA2R-AB in longitudinal serum samples revealed seropositivity in 44% (59 out of 134) of primary MN cases, 3% (one out of 35) of secondary MN cases, and in 0% of healthy controls. Among patients with MN, PLA2R-AB were detectable at a median of 274 days before renal biopsy diagnosis (interquartile range, 71–821 days). Approximately one third of the participants became seropositive within 3 months of MN diagnosis. Of the 21 individuals with documented prediagnostic NNRP, 43% (nine out of 21) were seropositive before NNRP was first documented and 28.5% (six out of 21) were seropositive at the same time as NNRP; 66% (39 out of 59) of those seropositive for PLA2R-AB had hypoalbuminemia present at the time antibody was initially detected. Twelve participants (20%) were seropositive before hypoalbuminemia became apparent, and eight participants (14%) were seropositive after hypoalbuminemia became apparent. Conclusions Circulating PLA2R-AB are detectable months to years before documented NNRP and biopsy-proven diagnosis in patients with MN.Keywords
Funding Information
- National Institute of Dental and Craniofacial Research
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institute of Dental and Craniofacial Research (ZIC DE000729-09)
This publication has 41 references indexed in Scilit:
- Autoantibodies are present before the clinical diagnosis of systemic sclerosisPLOS ONE, 2019
- PLA2R and THSD7A: Disparate Paths to the Same Disease?Journal of the American Society of Nephrology, 2017
- Epitope Spreading of Autoantibody Response to PLA2R Associates with Poor Prognosis in Membranous NephropathyJournal of the American Society of Nephrology, 2015
- Prediction of Sjögren's Syndrome Years Before Diagnosis and Identification of Patients With Early Onset and Severe Disease Course by Autoantibody ProfilingArthritis & Rheumatology, 2015
- Identification of a Major Epitope Recognized by PLA2R Autoantibodies in Primary Membranous NephropathyJournal of the American Society of Nephrology, 2015
- Identification of the Immunodominant Epitope Region in Phospholipase A2 Receptor-Mediating Autoantibody Binding in Idiopathic Membranous NephropathyJournal of the American Society of Nephrology, 2015
- Luciferase immunoprecipitation systems for measuring antibodies in autoimmune and infectious diseasesTranslational Research, 2015
- Asymptomatic Autoantibodies Associate with Future Anti-glomerular Basement Membrane DiseaseJournal of the American Society of Nephrology, 2011
- Anti-Phospholipase A2 Receptor Antibody in Membranous NephropathyJournal of the American Society of Nephrology, 2011
- Distribution of IgG subclasses in membranous nephropathy.1984